STR-P004
Phase 1Small molecule
STR-P004 is one of 104 small molecule programs targeting Kidney Disease. It is currently in Phase 1.
3
Indications
4
Total Trials
4
Active Trials
103
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Biaxin
AbbViePhase 3
Adriamycin
PfizerPhase 3
Soliris
AstraZenecaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Kidney Disease1 trial
Unspecified1 trial
Exploratory Clinical Study on the Safety of STR-P004
Recruiting·—·N/A·NCT07143617·39 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for STR-P004. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SStarna Therapeutics